Regional administration of class C CpG Oligodeoxynucleotides results in superior intrahepatic TLR9 activation and immunomodulation compared to systemic infusion.

被引：0
|
作者：
Ghosh, Chandra [1 ]
Heatherton, Kara [1 ]
O'Connell, Kyle [1 ]
Laporte, Jason [1 ]
Guha, Prajna [1 ]
Jaroch, David [2 ]
Cox, Bryan [2 ]
Katz, Steven C. [1 ]
机构：
[1] Roger Williams Med Ctr, Providence, RI USA
[2] Trisalus Life Sci, Westminster, CO USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1793
引用
收藏
页数：2
相关论文
共 5 条
  • [1] Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition
    Chandra C. Ghosh
    Kara R. Heatherton
    Kyle P. O’ Connell
    Ian S. Alexander
    Deborah A. Greer
    Jason LaPorte
    Prajna Guha
    Bryan F. Cox
    Steven C. Katz
    Cancer Gene Therapy, 2022, 29 : 1854 - 1865
  • [2] Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition
    Ghosh, Chandra C.
    Heatherton, Kara R.
    O' Connell, Kyle P.
    Alexander, Ian S.
    Greer, Deborah A.
    LaPorte, Jason
    Guha, Prajna
    Cox, Bryan F.
    Katz, Steven C.
    CANCER GENE THERAPY, 2022, 29 (12) : 1854 - 1865
  • [3] Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-Class CpG oligodeoxynucleotide TLR9 agonist
    Krieg, AM
    Efler, SM
    Wittpoth, M
    Al Adhami, MJ
    Davis, HL
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : 460 - 471
  • [4] PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion plus /-checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
    Lee, Sunyoung S.
    Almhanna, Khaldoun
    Sheth, Rahul
    Pant, Shubham
    Kuban, Joshua
    Maxwell, Aaron Wilhelm Palmer
    Witt, Brian Justin
    LaPorte, Jason
    Hulstine, Ann-Marie
    Cox, Bryan
    Carvajal, Richard D.
    White, Ruth Aroon
    Weintraub, Joshua
    Davis, Lindsey
    Hart, James
    Knight, Robert D.
    Katz, Steven C.
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial
    Levy, Ronald
    Reagan, Patrick M.
    Friedberg, Jonathan W.
    Bartlett, Nancy L.
    Gordon, Leo I.
    Leung, Abraham
    Peterkin, Joanna
    Xing, Biao
    Coffman, Robert
    Janssen, Robert
    Candia, Albert
    Khodadoust, Michael
    Frank, Matthew J.
    Long, Steven R.
    Czerwinski, Debra K.
    Chu, Michael
    BLOOD, 2016, 128 (22)
1